Course Listings: Oncology

All Results (10)
Format: Live Events (0) Online Activities (10)

Clinical Advances in Diagnostics and Therapies for FGFR-Altered Cancer: February 2021 Updates: Part Two

View Course

Format: Webcast

Maximum Credits: 1.75

Course Description: In this 2-hour webcast, experts explore the emerging science and research of targeting the FGFR signaling pathway and the current and future clinical applications of FGFR inhibitors in cancer care. A panel of experts then discuss how this science can be incorporated into practice.


Defining the Role of the Medical Oncologist in the Management of CSCC in the Age of Immunotherapy

View Course

Format: Med-IQ Select

Maximum Credits: 0.75

Course Description: This 45-minute, accredited CME activity discusses the pathophysiology of cutaneous squamous cell carcinoma (CSCC), rationale for the development of immune checkpoint inhibitors for this condition, current and emerging treatment approaches, and the importance of care coordination for patients with advanced CSCC. A case vignette highlights the appropriate…More


Decision-IQ: A Case-Based Overview of Screening for Lynch Syndrome in a Patient With Uterine Cancer

View Course

Format: Decision-IQ

Maximum Credits: 0.25

Course Description: This 15-minute, accredited CME publication follows the case of a patient who was referred to a gynecologist for uterine fibroids and heavy bleeding. Dr. Rebecca A. Previs provides insight on diagnosing this patient with Lynch syndrome and discusses current best practices for managing patients with this condition.


Therapeutic Targeting of HER3 in Breast and Lung Cancer: Preparing for the Future

View Course

Format: Med-IQ Select

Maximum Credits: 0.5

Course Description: This 30-minute accredited CME activity discusses the role of HER3 in cancer progression and treatment resistance in breast cancer and non–small cell lung cancer (NSCLC) and explores investigational therapies targeting HER3. In addition, brief audio clips provide expert perspectives about HER3-targeting agents and how they are expected to affect patient care for…More


Clinical Advances in Diagnostics and Therapies for FGFR-Altered Cancer: Part One

View Course

Format: Webcast

Maximum Credits: 2.0

Course Description: In this 2-hour webcast, experts explore the emerging science and research of targeting the FGFR signaling pathway and the current and future clinical applications of FGFR inhibitors in cancer care. A panel of experts then discuss how this science can be incorporated into practice.


Conquering Urothelial Carcinoma With FGFR Inhibitors: Moving Toward Personalized Medicine

View Course

Format: Med-IQ Select

Maximum Credits: 0.5

Course Description: This 30-minute activity explores the role of fibroblast growth factor receptor (FGFR) alterations in urothelial cancer (UC) pathogenesis and provides a summary of efficacy and safety data for available and emerging selective FGFR tyrosine kinase inhibitors for the treatment of UC. Whiteboard animation videos are used to show how these FGFR aberrations act as…More


Caring for Patients With Lung Cancer and Targetable Mutations: Guidance on EGFR, ALK, and ROS1

View Course

Format: E-Publication

Maximum Credits: 0.5

Course Description: In this case-based activity, meet 2 patients with advanced non–small cell lung cancer (NSCLC) who are starting treatment. How would you manage these patients? As you move through this activity, you will:See how your answers compare with your peers’ Read commentary on the answer optionsReview insights from medical oncologist, Suresh Ramalingam,…More


Perspectives in CHL Treatment: Addressing the Needs of Community Oncologists

View Course

Format: Med-IQ Select

Maximum Credits: 0.5

Course Description: This activity explores the unique challenges that community hematologists and oncologists face when managing patients with classic Hodgkin lymphoma (CHL) and helps these physicians integrate novel treatment strategies into their care of patients with this condition.


TROP2-Targeting Therapies in NSCLC: What You Need to Know

View Course

Format: Med-IQ Select

Maximum Credits: 0.5

Course Description: This 30-minute, accredited CME activity discusses the role of TROP2 in cancer development and the potential use of TROP2 antibody-drug conjugates in NSCLC treatment. In addition, brief audio clips provide expert perspectives about TROP2 antibody-drug conjugates and how they are expected to affect patient care once they are available for clinical use.


The Path Forward in Advanced HER2+ Gastric Cancer: More Options, More Decisions

View Course

Format: Med-IQ Select

Maximum Credits: 0.5

Course Description: This modular, accredited CME publication explores emerging research and practical insights related to the use of novel human epidermal growth factor receptor 2 (HER2) targeting agents in clinical development for the treatment of HER2 expressing gastric or gastroesophageal junction (GEJ) adenocarcinoma. Audio clips provide insights from expert faculty, Johanna…More




We recently updated our Privacy Notice and Terms of Use.